| Nov 26 |
Cassava Sciences: Phase 3 Alzheimer's Drug Fail The Final Nail In The Coffin
|
| Nov 26 |
Cassava Sciences Faces Reality After Simufilam's Phase 3 Failure
|
| Nov 26 |
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
|
| Nov 26 |
What’s left in Cassava after Phase 3 setback for Alzheimer’s drug
|
| Nov 26 |
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)
|
| Nov 26 |
Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today
|
| Nov 25 |
Cassava Sciences plummets over 80% on Alzheimer's trial fail
|
| Nov 25 |
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
|
| Nov 25 |
Cassava Sciences stock plummets after Phase III Alzheimer’s fail
|
| Nov 25 |
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
|
